Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

SAVE-MORE
  NCT04680949		 RCTanakinraplaceboCOVID 19 hospitalizedlow
412/194 conclusif
  • suggested 55 % decrease in deaths with a high degree of certainty due to low risk of bias
  • demonstrated 64 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias

COVID-19 mild to moderate meta-analysis

CORIMUNO-ANA-1
  NCT04341584		 RCTanakinracontrolCOVID-19 mild to moderatesome concern
59/57 inconclusive
    LIVE-AIR (Temesgen)
          NCT04351152    		 RCTlenzilumabplaceboCOVID-19 mild to moderatesome concern
    		261/259 conclusif
    • demonstrated 35 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    Fakharian
          IRCT20151227025726N2    		 RCTadalimumabCOVID-19 severe or criticallysome concern
    		34/34 ongoing
      CAN-COVID
              NCT04362813      		 RCTcanakinumabplaceboCOVID-19 severe or criticallysome concern
      		227/227 inconclusive
      • inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
      2 studies excluded by filtering options (2 RCT / 0 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons